Thompson Siegel & Walmsley LLC Has $14.21 Million Position in CVS Health Co. (NYSE:CVS)

Thompson Siegel & Walmsley LLC reduced its position in shares of CVS Health Co. (NYSE:CVS) by 2.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 205,520 shares of the pharmacy operator’s stock after selling 4,269 shares during the quarter. Thompson Siegel & Walmsley LLC’s holdings in CVS Health were worth $14,208,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the company. Cantor Fitzgerald Investment Advisor L.P increased its position in CVS Health by 92.9% during the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 377,875 shares of the pharmacy operator’s stock worth $38,245,000 after buying an additional 181,966 shares during the last quarter. United Bank increased its position in CVS Health by 7.2% during the first quarter. United Bank now owns 18,658 shares of the pharmacy operator’s stock worth $1,888,000 after buying an additional 1,260 shares during the last quarter. Loomis Sayles & Co. L P increased its position in CVS Health by 4,063.8% during the first quarter. Loomis Sayles & Co. L P now owns 12,075 shares of the pharmacy operator’s stock worth $1,222,000 after buying an additional 11,785 shares during the last quarter. Zions Bancorporation N.A. increased its position in CVS Health by 116.9% during the first quarter. Zions Bancorporation N.A. now owns 2,572 shares of the pharmacy operator’s stock worth $260,000 after buying an additional 1,386 shares during the last quarter. Finally, Ergoteles LLC acquired a new position in CVS Health during the first quarter worth $1,551,000. 75.99% of the stock is owned by institutional investors and hedge funds.

CVS Health Price Performance

NYSE:CVS traded up $0.56 during mid-day trading on Friday, hitting $68.81. The company’s stock had a trading volume of 6,447,995 shares, compared to its average volume of 7,437,639. CVS Health Co. has a fifty-two week low of $64.41 and a fifty-two week high of $104.83. The company has a current ratio of 0.86, a quick ratio of 0.64 and a debt-to-equity ratio of 0.80. The company has a market capitalization of $88.55 billion, a price-to-earnings ratio of 10.38, a P/E/G ratio of 1.78 and a beta of 0.58. The stock has a fifty day moving average of $69.87 and a 200-day moving average of $70.02.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, November 1st. The pharmacy operator reported $2.21 earnings per share for the quarter, topping the consensus estimate of $2.13 by $0.08. The company had revenue of $89.76 billion during the quarter, compared to analyst estimates of $88.29 billion. CVS Health had a net margin of 2.47% and a return on equity of 15.36%. The company’s revenue was up 10.6% on a year-over-year basis. During the same quarter last year, the business posted $2.09 earnings per share. As a group, equities analysts forecast that CVS Health Co. will post 8.59 EPS for the current fiscal year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, November 1st. Stockholders of record on Friday, October 20th were issued a dividend of $0.605 per share. This represents a $2.42 annualized dividend and a dividend yield of 3.52%. The ex-dividend date of this dividend was Thursday, October 19th. CVS Health’s payout ratio is 36.50%.

Wall Street Analyst Weigh In

A number of research firms have issued reports on CVS. Raymond James decreased their price target on shares of CVS Health from $90.00 to $85.00 and set an “outperform” rating for the company in a report on Friday, August 4th. StockNews.com cut shares of CVS Health from a “buy” rating to a “hold” rating in a report on Monday, November 6th. Piper Sandler decreased their price target on shares of CVS Health from $85.00 to $82.00 and set an “overweight” rating for the company in a report on Friday, September 1st. TheStreet upgraded shares of CVS Health from a “c” rating to a “b-” rating in a report on Wednesday, November 1st. Finally, Wolfe Research upgraded shares of CVS Health from a “peer perform” rating to an “outperform” rating and set a $80.00 price target for the company in a report on Tuesday, September 12th. Four research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat.com, CVS Health has an average rating of “Moderate Buy” and a consensus price target of $92.59.

Insider Transactions at CVS Health

In other news, Director Edward J. Ludwig acquired 2,000 shares of the company’s stock in a transaction dated Friday, November 3rd. The stock was bought at an average price of $70.47 per share, with a total value of $140,940.00. Following the completion of the acquisition, the director now owns 20,630 shares in the company, valued at approximately $1,453,796.10. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 0.25% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation provides health services in the United States. It operates through Health Care Benefits, Pharmacy Services, and Retail/LTC segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates.